Skip to content

13F-HR filed by Cormorant Asset Management, LP

Cormorant Asset Management, LP filed this 13F-HR for the quarter ended 2013-12-31, filed 2014-02-14, with 37 holding rows worth $344,568,000.

Accession
0001140361-14-007278
Filed
2014-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2013

A holdings report, 37 entries on the cover page, a total value of $344,568,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $344,573,000 with VALUE read as thousands by filing date, 13F file number 028-15949. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MEDIVATION INC58501N101COM546,900$34,903,000thousands by filing date
CUBIST PHARMACEUTICALS INC229678107COM400,000$27,548,000thousands by filing date
KERYX BIOPHARMACEUTICALS492515101COMMON STOCK1,700,000$22,015,000thousands by filing date
DYAX CORP26746E103COM2,850,000$21,475,000thousands by filing date
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK200,000$20,706,000thousands by filing date
CELGENE CORP151020104COM120,000$20,276,000thousands by filing date
ACADIA PHARMACEUTICALS INC004225108COM800,000$19,992,000thousands by filing date
IDENIX PHARMACEUTICALS INC45166R204COM2,925,000$17,492,000thousands by filing date
GERON CORP374163103COM3,397,156$16,103,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock250,000$16,075,000thousands by filing date
Bristol-Myers Squibb Company110122108COM270,000$14,351,000thousands by filing date
ARROWHEAD RESEARCH CORP042797209COM995,500$10,801,000thousands by filing date
DEXCOM INC COM252131107Stock300,000$10,623,000thousands by filing date
RECEPTOS, INC.756207106COMMON STOCK350,000$10,147,000thousands by filing date
ARRAY BIOPHARMA INC COM04269X105Stock1,750,000$8,768,000thousands by filing date
ACELRX PHARMACEUTICALS INC00444T100COM750,000$8,483,000thousands by filing date
TESARO INC881569107COM300,000$8,472,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM119,300$7,190,000thousands by filing date
BIOMARIN PHARMACEUTICAL INC09061G101COM100,000$7,035,000thousands by filing date
Alkermes Plc00B56GVS1common150,000$6,099,000thousands by filing date
AMAG PHARMACEUTICALS INC00163U106COM250,000$6,070,000thousands by filing date
INSULET CORP COM45784P101Stock150,000$5,565,000thousands by filing date
NOVAVAX INC670002104COMMON STOCK1,000,000$5,120,000thousands by filing date
PACIRA BIOSCIENCES INC COM695127100Stock50,000$2,875,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM166,200$2,309,000thousands by filing date
KARYOPHARM THERAPEUTICS INC48576U106COM100,000$2,292,000thousands by filing date
CHIMERIX INC COM16934W106Stock143,000$2,161,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock268,000$2,037,000thousands by filing date
PORTOLA PHARMACEUTICALS INC COM737010108Stock75,000$1,931,000thousands by filing date
OSIRIS THERAPEUTICS INC NEW68827R108COM107,800$1,733,000thousands by filing date
XENOPORT INC98411C100COM200,000$1,150,000thousands by filing date
REGULUS THERAPEUTICS INC75915K101COM100,000$739,000thousands by filing date
MOMENTA PHARMACEUTICALS INC60877T100COM27,700$490,000thousands by filing date
PTC THERAPEUTICS INC69366J200COM28,800$489,000thousands by filing date
DENDREON CORP24823Q107COM150,000$449,000thousands by filing date
FIVE PRIME THERAPEUTICS INC.33830X104Common Stock20,000$336,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM10,000$273,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001140361-14-007278this filing2014-02-14acceptance time not in the bulk data set